Aurobindo adds to manufacturing with biosimilars plant

Syringes
Aurobindo says it is building a plant in India to produce biosimilars.

India’s Aurobindo Pharma has acquired four biosimilar products from a Swiss company and says it is building a manufacturing plant to support the production of those and eight others it has under development.

The Indian company reported last week that it has acquired the biosimilars from Visp-based TL Biopharmaceutical. Details on the deal were scarce, but it said they include three oncology monoclonal antibodies, including bevacizumab, a biosimilar of Roche’s cancer drug Avastin.

Terms of the deal were not divulged, but about 14 months ago a report in Livemint said that Aurobindo was negotiating a $200 million deal with an EU company for the rights to bevacizumab, as well as biosimolars of Roche's breast cancer treatment Herceptin, Johnson & Johnson's autoimmune blockbuster Remicade, and Amgen's rheumatoid arthritis drug Enbrel.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

It said in the announcement that it would expand the four products picked up from TL with “eight more next wave of biosimilars.”

The Indian company said in its announcement that it was building a state-of-the-art manufacturing facility in Hyderabad, Telangana, for manufacturing all of the drugs. It expects the plant to be complete in the second quarter of fiscal 2018, which would mean sometime in the second half of this calendar year.

The news comes just a week after Aurobindo indicated it would build a second sterile injectables plant on a site in New Jersey, partly in response to tax talk from President Trump.

"With the current landscape of what's happening with the U.S. White House administration, and some of the things that may change there, clearly, we don't think having capacity in the U.S. would be detrimental at this point," Bob Cunard, head of Aurobindo’s U.S. operations, said in an earnings briefing, Reuters reported.

The drugmaker began work in August on a 567,000-square-foot facility in New Jersey that is slated to include a manufacturing and distribution center and warehouse that will eventually employ 400 to 500.

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.